We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
ZeptoMetrix an Antylia scientific company

Download Mobile App




New Blood Test to Measure Omega-3 Fatty Acids Could Help Evaluate Cardiovascular Risks

By LabMedica International staff writers
Posted on 13 Oct 2023
Print article
Image: Researchers have developed a new test to measure omega-3 fatty acids in blood (Photo courtesy of 123RF)
Image: Researchers have developed a new test to measure omega-3 fatty acids in blood (Photo courtesy of 123RF)

The human body can produce many of the fats it requires, but omega-3 fatty acids must come from our diet. These essential fatty acids, specifically EPA and DHA, are mainly found in sources like fish, seafood, and certain enriched foods and supplements. A deficiency in these fatty acids can increase cardiovascular risks and is linked to issues like inflammation, mental decline, depression, and problems in fetal brain development and premature births. Currently, assessing omega-3 levels in the blood is challenging and involves an invasive blood test. Now, researchers have come up with a more convenient method to monitor these crucial fatty acids in the blood, making it easier to collect vital health data related to cardiovascular and cognitive health.

Researchers at McMaster University (Hamilton, ON, Canada) have identified a new biomarker for the Omega-3 Index (O3I) which makes it simpler to study the role of omega-3 fatty acid nutrition for overall public health, including among at-risk populations. Traditional methods for assessing O3I have involved drawing significant amounts of blood and complex lab procedures, making it an uncommon practice among healthcare providers. This new technique could enable regular screening, assisting both doctors and patients in determining the appropriate level of supplementation.

Generally, an O3I lower than 4% signifies a greater risk for cardiovascular issues, while an O3I above 8% suggests a lower risk. Importantly, the O3I can be modified through dietary changes. In the study, subjects were administered between 3 to 5 grams of fish oil, EPA, or DHA supplements daily. The research team conducted lipid profiling to pinpoint specific O3I biomarkers from the hundreds of lipids that can be found in the blood. The researchers are also working on identifying a substitute biomarker for the O3I through a urine test, which would eliminate the need for blood draws altogether.

“Our test can be part of a routine blood test without any special requirements,” says lead author Philip Britz-McKibbin, a professor of chemistry and chemical biology at McMaster. “By directly measuring only two specific biomarkers in a blood sample, we can rapidly assess the Omega-3 Index without time-consuming and costly sample workup protocols prior to analysis.”

Related Links:
McMaster University

Gold Member
Pharmacogenetics Panel
VeriDose Core Panel v2.0
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Silver Member
H-FABP Assay
Heart-Type Fatty Acid-Binding Protein Assay
New
C-Reactive Protein Assay
OneStep C-Reactive Protein (CRP) RapiCard InstaTest

Print article

Channels

Clinical Chemistry

view channel
Image: The GlycoLocate platform uses multi-omics and advanced computational biology algorithms to diagnose early-stage cancers (Photo courtesy of AOA Dx)

AI-Powered Blood Test Accurately Detects Ovarian Cancer

Ovarian cancer ranks as the fifth leading cause of cancer-related deaths in women, largely due to late-stage diagnoses. Although over 90% of women exhibit symptoms in Stage I, only 20% are diagnosed in... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: The new algorithms can help predict which patients have undiagnosed cancer (Photo courtesy of Adobe Stock)

Advanced Predictive Algorithms Identify Patients Having Undiagnosed Cancer

Two newly developed advanced predictive algorithms leverage a person’s health conditions and basic blood test results to accurately predict the likelihood of having an undiagnosed cancer, including ch... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.